A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Trial Profile

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs STRO 001 (Primary)
  • Indications Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Sutro Biopharma
  • Most Recent Events

    • 22 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 12 Dec 2017 According to a Sutro Biopharma media release, company plans to submit IND application by the end of 2017 and initiate the trial in Q1 2018.
    • 19 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top